J. Ross

J. Ross, V. Velcheti, Siraj M. Ali, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Breast cancer biomarkers and molecular medicine: part II

Lajos Pusztai, Mark Ayers, J. Stec, 2004, Expert review of molecular diagnostics.

Multigene Classifiers, Prognostic Factors, and Predictors of Breast Cancer Clinical Outcome

J. Ross, J. Ross, 2009, Advances in anatomic pathology.

Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.

Roman Rouzier, Lajos Pusztai, Kenneth R Hess, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Actin‐binding protein fascin expression in skin neoplasia

J. Ross, J. Carlson, V. Goncharuk, 2002, Journal of cutaneous pathology.

Three-dimensional FLASH imaging: applications with gadolinium-DTPA.

J. Ross, M. Modic, T. Masaryk, 1989, Journal of computer assisted tomography.

The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy

J. Ross, J. Fletcher, Jonathan A. Fletcher, 1998, The oncologist.

A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases

P. Hegde, J. Ross, B. Alexander, 2020, Modern Pathology.

E‐cadherin cell‐adhesion molecule expression as a diagnostic adjunct in urothelial cytology

J. Ross, C. Sheehan, H. Fisher, 1996, Diagnostic cytopathology.

Prognostic factors in gastric cancer.

J. Ross, T. Brien, C. Sheehan, 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

Clinicopathologic Features of a Series of Primary Renal CIC-rearranged Sarcomas With Comprehensive Molecular Analysis

M. Shago, J. Ross, P. Argani, 2018, The American journal of surgical pathology.

HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary.

J. Ross, C. Sheehan, P. Muraca, 1999, American journal of clinical pathology.

GAMMA KNIFE RADIOSURGERY FORGLOMUS JUGULARE TUMORS

N. Nathoo, J. Ross, G. Barnett, 2006 .

GAMMA KNIFE RADIOSURGERY FOR GLOMUS JUGULARE TUMORS: VOLUMETRIC ANALYSISIN 17 PATIENTS

N. Nathoo, J. Ross, G. Barnett, 2006, Neurosurgery.

Clinical and immunological implications of frameshift mutations in lung cancer.

Jeffrey H. Chuang, J. Ross, E. Sokol, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Dual Targeting of EGFR and IGF1R in the TNFAIP8 Knockdown Non–Small Cell Lung Cancer Cells

J. Ross, C. Sheehan, U. Kasid, 2019, Molecular Cancer Research.

A Novel SDHA-deficient Renal Cell Carcinoma Revealed by Comprehensive Genomic Profiling

J. Ross, Siraj M. Ali, A. Brodsky, 2015, The American journal of surgical pathology.

Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study.

J. Ross, U. Capitanio, F. Montorsi, 2019, European urology.

Telomerase Activity in Human Benign Prostate Tissue and Prostatic Adenocarcinomas

J. Ross, T. Brien, B. Kallakury, 1997, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

Molecular Techniques in Cancer Diagnosis and Management

J. Stec, J. Ross, R. Mosher, 2004 .

Vascular Gene Discovery Using Laser Capture Microdissection of Human Blood Vessels and Quantitative PCR

J. Ross, N. Stagliano, M. Donovan, 2001, Annals of the New York Academy of Sciences.

Newer sequences for spinal MR imaging: smorgasbord or succotash of acronyms?

J. Ross, Jonathan J Ross, J. Ross, 1999, AJNR. American journal of neuroradiology.

Volume T1‐Weighted Gradient Echo MRI in Multiple Sclerosis Patients

N. Obuchowski, J. Ross, R. Rudick, 1992, Journal of computer assisted tomography.

Prognostic significance of HER‐2/neu gene amplification status by fluorescence in Situ hybridization of prostate carcinoma

J. Ross, M. Rifkin, C. Sheehan, 1997, Cancer.

Carotid bifurcation: MR imaging. Work in progress.

J. Ross, E. Haacke, M. Modic, 1988, Radiology.

Comparing two assays for clinical genomic profiling: the devil is in the data

J. Ross, V. Miller, G. Frampton, 2015, OncoTargets and therapy.

Survivin and Bcl-2 expression in prostatic adenocarcinomas.

J. Ross, C. Sheehan, B. Kallakury, 2009, Archives of pathology & laboratory medicine.

Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study.

J. Ross, F. Montorsi, A. Salonia, 2020, Clinical genitourinary cancer.

Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.

J. Ross, A. Maitra, V. Miller, 2019, Gastroenterology.

Co-downregulation of cell adhesion proteins α- and β-catenins, p120CTN, E-cadherin, and CD44 in prostatic adenocarcinomas

J. Ross, C. Sheehan, B. Kallakury, 2001 .

E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage, and clinical outcome.

J. Ross, H. Fisher, H. Figge, 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas.

J. Ross, C. Sheehan, P. Muraca, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetic Alterations and Tumor Mutation Burden of Poorly Differentiated Small Cell Euro-endocrine Carcinomas are Similar in Lung Lesions and Distant Metastatic Foci

P. Stephens, J. Ross, E. Sokol, 2018 .

Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma.

J. Ross, V. Miller, G. Frampton, 2019, Journal of the American Academy of Dermatology.

Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2–positive breast cancer cells in a synergistic manner

C. Sotiriou, C. Desmedt, M. Piccart, 2006, Molecular Cancer Therapeutics.

Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations

J. Ross, E. Sokol, B. Alexander, 2020, Modern Pathology.

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.

J. Ross, E. Sokol, V. Miller, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical response to everolimus in a patient with Hodgkin's lymphoma harboring a TSC2 mutation

J. Ross, P. Campregher, Siraj M. Ali, 2016, Blood Cancer Journal.

Emerging science: Prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer

J. Stec, M. Ayers, J. Ross, 2003 .

Atherosclerosis and cancer: common molecular pathways of disease development and progression.

G. Ginsburg, J. Ross, N. Stagliano, 2001, Annals of the New York Academy of Sciences.

A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma

Kai Wang, Timothy A Jennings, Doron Lipson, 2013, Clinical Cancer Research.

The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer

J. Ross, Hwajeong Lee, J. Ross, 2017, Therapeutic advances in gastroenterology.

Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets

David M. Jones, P. Stephens, R. Yelensky, 2015, Journal of Clinical Pathology.

ComprehensiveGenomicProfilingofAdvancedEsophagealSquamous CellCarcinomasandEsophagealAdenocarcinomasRevealsSimilarities and Differences

P. Stephens, R. Yelensky, J. Ross, 2015 .

Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer.

James X. Sun, J. Ross, V. Miller, 2016 .

Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib.

P. Stephens, J. Ross, D. Lipson, 2014, Clinical breast cancer.

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations

P. Stephens, J. Ross, M. Rosenzweig, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma

M. Kris, C. Azzoli, J. Ross, 2005, Cancer.

On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation

Benjamin P. Brown, J. Ross, J. Meiler, 2019, Clinical Cancer Research.

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.

P. Stephens, J. Ross, S. Ou, 2015, Lung cancer.

Diagnosis of cerebrovascular disease in sickle cell anemia by magnetic resonance angiography.

J. Ross, M. Wiznitzer, M. Modic, 1990, The Journal of pediatrics.

Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.

Krishna R. Kalari, James X. Sun, K. Kalari, 2015, Journal of the National Cancer Institute.

HER-2/neu Gene and protein in breast cancer

C. Sotiriou, J. Ross, G. Hortobagyi, 2004 .